Hairy Cell HCP
Program Description: Despite advances in treatment, hairy cell leukemia (HCL) remains a challenge to recognize and diagnose. While first-line treatment is standardized and survival is high, roughly 50% of patients will relapse within 16 years. At this point, treatment decisions become more complex introducing variability in disease management and monitoring. Experts in HCL will discuss pertinent clinical application scenarios designed to facilitate better molecular characterization, address the growing role of minimal residual disease as a prognostic and monitoring strategy, adhere to clinical guidelines and specific response criteria in HCL, provide evidence-based rationale for current therapies, and highlight new data from recent key meetings including promising therapies in HCL.